Autosomal recessive mendelian susceptibility to mycobacterial diseases due to a partial deficiency
aw-toh-SOH-muhl ree-SEH-siv MEN-dee-lee-un suh-sep-tuh-BIL-ih-tee to my-koh-BAK-teer-ee-ul dih-ZEEZ due to a PAR-shuhl dih-FISH-en-see
Also known as: MSMD, Partial IFN-γ pathway deficiency
At a Glance
What is Autosomal recessive mendelian susceptibility to mycobacterial diseases due to a partial deficiency?
This condition is a genetic disorder that affects the immune system, making individuals more susceptible to infections by mycobacteria. It primarily impacts the immune system, particularly the pathways involving interferon-gamma, which is crucial for fighting off certain infections. The disorder is caused by mutations in genes responsible for immune responses, leading to partial deficiencies in these pathways. Over time, affected individuals may experience recurrent infections, which can become more severe if not properly managed. Early symptoms might include frequent respiratory infections, while later symptoms could involve more serious infections like tuberculosis. Early diagnosis is critical to manage infections effectively and prevent complications. The condition can significantly impact family life, as it requires ongoing medical care and monitoring. The prognosis varies depending on the severity of the deficiency and the effectiveness of treatment. Daily life for affected individuals may involve regular medical check-ups, preventive measures to avoid infections, and sometimes lifelong treatments. Families may need to adapt their lifestyle to reduce exposure to potential infections. With appropriate medical care, many individuals can lead relatively normal lives. However, they must remain vigilant about their health and infection risks.
Medical Definition
Autosomal recessive mendelian susceptibility to mycobacterial diseases due to a partial deficiency is characterized by a genetic defect in the interferon-gamma (IFN-γ) signaling pathway. Pathologically, this results in impaired macrophage activation and defective immune responses to mycobacterial infections. Histological findings often show granulomas with necrosis due to the body's inability to effectively contain mycobacterial pathogens. The condition is classified under primary immunodeficiencies and is part of a broader group of disorders affecting the IFN-γ pathway. Epidemiologically, it is a rare condition with a prevalence of approximately 1 in 500,000 individuals. The disease course can vary, with some patients experiencing mild symptoms while others may have severe, life-threatening infections if not properly managed.
Autosomal recessive mendelian susceptibility to mycobacterial diseases due to a partial deficiency Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Recurrent mycobacterial infections manifest as persistent or recurrent fevers, weight loss, and chronic cough. This is caused by a partial deficiency in the immune response, specifically affecting the interferon-gamma pathway. Over time, these infections can lead to significant tissue damage and organ dysfunction if not properly managed. Patients often require long-term antibiotic therapy and regular monitoring to manage these infections effectively.
Lymphadenopathy presents as swollen or enlarged lymph nodes, often in the neck or armpits. It occurs due to the immune system's response to mycobacterial infections, where lymph nodes become sites of infection or inflammation. If untreated, the swelling can become chronic and may lead to abscess formation. Patients may experience discomfort or pain, and surgical intervention may be necessary in severe cases.
Fever is a common symptom characterized by an elevated body temperature, often accompanying infections. It results from the body's inflammatory response to mycobacterial pathogens. Persistent or recurrent fevers can lead to fatigue and dehydration if not managed. Antipyretics and adequate hydration are essential to manage fever and improve patient comfort.
Common
Chronic cough is a persistent cough lasting more than eight weeks, often associated with mycobacterial lung infections. It occurs due to inflammation and irritation of the airways caused by the infection. Over time, the cough can become debilitating, affecting sleep and daily activities. Treatment involves addressing the underlying infection and may include cough suppressants for symptomatic relief.
Weight loss is a reduction in body weight that is often unintentional and associated with chronic infections. It is caused by increased metabolic demands and decreased appetite due to ongoing illness. If not addressed, significant weight loss can lead to malnutrition and weakened immunity. Nutritional support and management of the underlying infection are crucial to prevent further weight loss.
Fatigue is a feeling of persistent tiredness or exhaustion that is not relieved by rest. It results from the body's ongoing battle against chronic infections and the energy demands of an activated immune system. Over time, fatigue can severely impact a patient's quality of life, limiting their ability to perform daily activities. Management includes treating the underlying infection and ensuring adequate rest and nutrition.
Less Common
Skin lesions may appear as nodules, ulcers, or rashes on the skin, often at sites of mycobacterial infection. They are caused by the direct invasion of mycobacteria into the skin or as a result of the immune response. If untreated, these lesions can become chronic and may lead to scarring. Topical treatments and antibiotics are often required to manage and heal the lesions.
Hepatosplenomegaly is the enlargement of the liver and spleen, often detected during a physical examination. It occurs due to the accumulation of immune cells and mycobacterial organisms in these organs. Over time, significant enlargement can lead to abdominal discomfort and impaired organ function. Regular monitoring and treatment of the underlying infection are necessary to manage this condition.
What Causes Autosomal recessive mendelian susceptibility to mycobacterial diseases due to a partial deficiency?
Autosomal recessive mendelian susceptibility to mycobacterial diseases is primarily caused by mutations in genes such as IFNGR1 and IFNGR2, located on chromosomes 6q23.3 and 21q22.11, respectively. These genes encode the interferon-gamma receptor 1 and 2 proteins, which are crucial for the immune response against mycobacterial infections. Mutations in these genes can lead to truncated proteins or misfolding, impairing their ability to bind interferon-gamma effectively. This disruption results in a failure to activate the JAK-STAT signaling pathway, which is essential for the transcription of genes involved in the immune response. Consequently, macrophages and other immune cells cannot mount an effective response to mycobacterial pathogens. The dysfunction in this pathway leads to inadequate production of reactive oxygen species and other antimicrobial agents. Neighboring cells and tissues become susceptible to infection and inflammation due to the impaired immune response. Neuroinflammation may occur as a secondary effect of systemic infection and immune dysregulation. Over time, the chronic inflammatory state can lead to degeneration of white matter and other structures, although this is not a primary feature of the disease. Symptoms typically appear as recurrent infections, particularly with non-tuberculous mycobacteria, due to the specific role of the affected pathway in controlling these pathogens. The variability in disease severity among patients can be attributed to the specific nature of the mutations, residual function of the proteins, and potential involvement of other genetic or environmental factors. Some patients may have partial receptor function, leading to milder symptoms, while others with complete loss of function experience more severe disease. Additionally, genetic background and other immune-modulating factors can influence the clinical presentation. Understanding these molecular and cellular mechanisms is crucial for developing targeted therapies for affected individuals.
How is Autosomal recessive mendelian susceptibility to mycobacterial diseases due to a partial deficiency Diagnosed?
Typical age of diagnosis: Diagnosis typically occurs in early childhood when recurrent infections, particularly with mycobacteria, prompt further investigation. A detailed family history of similar infections may raise suspicion of a genetic predisposition. Early recognition is crucial to prevent severe complications. Genetic counseling is often recommended for families with a history of this condition.
Clinicians look for recurrent infections, particularly with atypical mycobacteria, and a history of similar infections in family members. Important history elements include the age of onset of infections and any previous hospitalizations for severe infections. Physical examination may reveal lymphadenopathy or hepatosplenomegaly. This step helps to identify patients who may benefit from further genetic testing.
Chest X-rays or CT scans are often used to identify lung abnormalities such as granulomas or cavitary lesions. These imaging findings can support the diagnosis by revealing characteristic changes associated with mycobacterial infections. Imaging helps confirm the presence of infection and rule out other causes of lung disease. Differential diagnoses such as primary immunodeficiencies or chronic granulomatous disease may be excluded based on imaging results.
Specific tests include complete blood counts and immunological assays to assess immune function. Biomarkers such as IFN-γ levels are sought to evaluate the immune response to mycobacterial antigens. Abnormal results may show impaired IFN-γ signaling or low levels of specific antibodies. These results guide the decision to pursue genetic testing and further immunological evaluation.
Genes such as IFNGR1, IFNGR2, and STAT1 are sequenced to identify mutations. Mutations may include missense, nonsense, or splice-site changes affecting protein function. Positive results confirm the diagnosis by demonstrating a genetic basis for the susceptibility. Genetic testing results are crucial for family counseling and assessing the risk of recurrence in future offspring.
Autosomal recessive mendelian susceptibility to mycobacterial diseases due to a partial deficiency Treatment Options
Antimycobacterial drugs such as rifampicin and isoniazid are used to treat infections. These drugs work by inhibiting bacterial cell wall synthesis and protein production. Specific drug regimens are tailored based on the type of mycobacterial infection and patient response. Clinical evidence supports their efficacy in reducing infection severity and frequency. Limitations include potential hepatotoxicity and drug interactions.
Techniques such as chest physiotherapy and breathing exercises are employed. The goal is to improve lung function and clear respiratory secretions. Sessions are typically conducted several times a week for optimal results. Measurable outcomes include improved lung capacity and reduced respiratory infections. Long-term benefits include enhanced quality of life and reduced hospitalizations.
Surgery may be indicated for persistent or symptomatic lymphadenopathy. The procedure involves the removal of affected lymph nodes to alleviate symptoms. Expected benefits include reduced pain and prevention of further complications. Surgical risks include infection and bleeding, requiring careful post-operative monitoring. Post-operative care involves wound management and monitoring for signs of recurrence.
The care team includes immunologists, infectious disease specialists, and genetic counselors. Interventions focus on infection prevention, nutritional support, and vaccination updates. Psychosocial support strategies involve counseling and support groups for patients and families. Family education covers disease management and genetic implications. Long-term monitoring involves regular follow-up visits to assess treatment efficacy and adjust care plans.
When to See a Doctor for Autosomal recessive mendelian susceptibility to mycobacterial diseases due to a partial deficiency
- Severe respiratory distress — this can indicate a life-threatening infection requiring immediate medical attention.
- High fever with chills — may suggest a serious systemic infection needing urgent evaluation.
- Confusion or altered mental status — could be a sign of severe infection affecting the brain or other organs.
- Persistent cough or difficulty breathing — could indicate a chronic infection that needs medical evaluation.
- Unexplained weight loss — may suggest ongoing infection or malnutrition requiring further investigation.
- Recurrent infections — indicates potential immune system issues that should be assessed by a healthcare provider.
- Mild fatigue — monitor energy levels and ensure adequate rest and nutrition.
- Occasional mild cough — keep track of frequency and severity, and consult a doctor if it worsens.
Autosomal recessive mendelian susceptibility to mycobacterial diseases due to a partial deficiency — Frequently Asked Questions
Is this condition hereditary?
This condition is inherited in an autosomal recessive pattern, meaning both parents must be carriers for a child to be affected. The probability of passing the condition to children is 25% if both parents are carriers. De novo mutations are rare but possible. Carrier status can have implications for family planning, and genetic counseling is recommended for affected families. Genetic counseling can provide information on carrier testing and reproductive options.
What is the life expectancy for someone with this condition?
Life expectancy varies depending on the age of onset and severity of infections. Early diagnosis and treatment can improve outcomes significantly. Mortality is often due to severe, recurrent infections. With appropriate medical management, individuals can have a near-normal life expectancy. Realistic expectations include ongoing medical care and monitoring.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves genetic testing and evaluation of immune function, often initiated by an immunologist. The time from first symptoms to diagnosis can vary, often taking several months. Specialists such as infectious disease experts and geneticists are typically consulted. Delayed diagnosis may occur due to the rarity of the condition and nonspecific symptoms. Confirmation is achieved through genetic testing identifying specific mutations.
Are there any new treatments or clinical trials available?
Current research is exploring gene therapy and novel immunomodulatory treatments. Clinical trials can be found on ClinicalTrials.gov by searching for the condition. Patients should discuss potential participation in trials with their healthcare provider. It's important to ask about the risks and benefits of new treatments. New treatments may become available in the next few years as research progresses.
How does this condition affect daily life and activities?
The condition can impact mobility and self-care due to frequent infections and fatigue. Educational accommodations may be needed for children with frequent absences. Social and emotional challenges include coping with chronic illness and potential isolation. Family burden can be significant, requiring support and resources. Adaptations such as home healthcare and educational support can help manage daily life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.
Niehues T, von Hardenberg S, Velleuer E · Allergol Select · 2024 · PMID: 39381601
- 2.Mendelian susceptibility to mycobacterial disease: 2014-2018 update.
Rosain J, Kong XF, Martinez-Barricarte R et al. · Immunol Cell Biol · 2019 · PMID: 30264912
- 3.Patient iPSC-Derived Macrophages to Study Inborn Errors of the IFN-γ Responsive Pathway.
Haake K, Neehus AL, Buchegger T et al. · Cells · 2020 · PMID: 32093117
- 4.Haploinsufficiency at the human IFNGR2 locus contributes to mycobacterial disease.
Kong XF, Vogt G, Itan Y et al. · Hum Mol Genet · 2013 · PMID: 23161749
- 5.The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases.
Al-Muhsen S, Casanova JL · J Allergy Clin Immunol · 2008 · PMID: 19084105
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-30